BioMarin Pharmaceutical Inc. (BMRN)

[chmcnfunds]

BioMarin Begins Phase 3 Trial Of BMN 673 For Metastatic GBRCA Breast Cancer

10/31/2013 5:31 AM ET

BioMarin Pharmaceutical Inc.(BMRN: Quote) Thursday said it has dosed the first patient in its Phase 3 program to study its poly ADP-ribose polymerase or PARP inhibitor, BMN 673, in the treatment of metastatic germline BRCA mutated breast cancer. The primary objective of the study is to measure progression free survival, while the secondary objectives include evaluating the objective response rate and the overall survival.

BRCA1 and BRCA2 are human genes that belong to a class of genes known as tumor suppressors. Mutation of these genes has been linked to hereditary breast and ovarian cancer.

Click here to receive FREE breaking news email alerts for Biomarin Pharmaceutical Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: [e-mail]
_________________________________________________
http://www.rttnews.com/2213556/biomarin-begins-phase-3-trial-of-bmn-673-for-metastatic-gbrca-breast-cancer.aspx?type=qf&utm_source=google&utm_campaign=sitemap

BMRN